查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2005153

抗體藥物複合體(ADC)契約製造市場：2026-2032 年全球市場預測（按服務類型、連接子類型、有效載荷類型、研發階段、劑型和應用分類）

Antibody Drug Conjugates Contract Manufacturing Market by Service Type, Linker Type, Payload Type, Development Stage, Dosage Form, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗體藥物複合體(ADC) 的契約製造市場價值將達到 106.5 億美元，到 2026 年將成長至 117.9 億美元，到 2032 年將達到 221 億美元，複合年成長率為 10.98%。

主要市場統計數據
基準年 2025 106.5億美元
預計年份：2026年 117.9億美元
預測年份 2032 221億美元
複合年成長率 (%) 10.98%

對專業契約製造如何改變抗體藥物複合體開發流程並降低技術和營運風險進行了權威分析。

抗體藥物複合體(ADC) 生態系統正處於關鍵轉折點，偶聯化學、有效載荷多樣性和精準遞送技術的進步與對專業契約製造日益成長的需求交匯融合。本執行摘要闡述了契約製造對於研發人員將 ADC 概念轉化為臨床和商業性現實的戰略重要性。本文著重分析了成功規模化生產與停滯不前的專案之間的能力差距、技術複雜性和營運里程碑。

鍵結化學、模組化服務模式和整合品質系統的進步如何重塑ADC開發商的合作夥伴選擇和製造策略。

抗體藥物偶聯物（ADC）產業正經歷著變革性的轉變，這主要得益於科學進步、服務模式的演變以及申辦者與生產商之間風險的重新分配。在科學層面，連接子化學、位點特異性結合以及新型有效載荷類型的創新，在拓展ADC治療應用的同時，也提高了生產精度的要求。這些技術進步推動了對檢驗製程、能夠提供穩定藥物抗體比例、低聚集率和可靠雜質控制的契約製造生產商的需求。

本研究評估了 2025 年關稅趨勢和貿易政策發展將如何重塑整個 ADC 製造價值鏈的採購、工廠位置和風險緩解策略。

2025年美國關稅政策的發展為ADC的契約製造策略帶來了新的複雜性，影響著採購、成本結構和策略供應鏈決策。某些化學中間體、合成試劑和部分進口生物製劑相關耗材的關稅提高，迫使製造商重新評估其供應商關係，並考慮近岸外包和雙重採購安排。在此背景下，關稅起到了戰略壓力測試的作用，凸顯了上游供應鏈的依賴性，並促使企業優先選擇貿易慣例合規且物流路線安全的供應商。

臨床階段、服務架構、有效載荷和連接子化學性質以及治療領域細分如何影響製造、品質和策略​​要求？

深入了解市場細分對於使生產能力與專案目標和監管要求相匹配至關重要。在市場上，計畫根據其類型按臨床和商業化階段進行區分，臨床階段又進一步細分為 I 期、II 期、III 期和臨床前活動。每個階段都有不同的技術和監管要求，從早期安全性檢驗所需的靈活小批量生產到後期主要試驗所需的受控且經過驗證的製程。認知這些差異，製造商就能最佳化生產能力和品質體系，以滿足申辦方的需求，同時縮短臨床試驗週期。

區域間在能力、法規結構和供應鏈複雜性方面的差異會影響ADC專案的選址、技術轉移和緊急時應對計畫。

區域趨勢影響全球抗體藥物偶聯物（ADC）生產網路中的生產能力、監管合作和物流複雜性。在美洲，領先的製造地將先進的生物製藥生產技術與成熟的法規結構相結合，從而促進從臨床到商業化的過渡，同時也為在地採購和快速進入市場提供了機會。相較之下，歐洲、中東和非洲地區的特點是監管路徑多樣，在專業化學領域和小批量GMP生產方面擁有強大的專業知識，但申辦方在協調跨境生產時必須應對各國監管差異和供應鏈中斷等問題。

技術深度、檢驗的品質系統和成熟的監管合規能力正成為ADC契約製造供應商的關鍵差異化因素。

製造業之間的競爭格局正在轉變，從單純提供生產能力轉向以技術能力、監管靈活性和綜合服務組合為基礎的價值主導差異化。領先的契約製造正在投資建造用於高等級有效載荷處理的專用設施，建立檢驗的生物偶聯平台，並擴展分析能力，以支持對抗體藥物偶聯物（ADC）關鍵品質屬性進行高級表徵。這些投資使合作夥伴公司能夠超越單純的交易關係，建立策略合作夥伴關係，從而縮短研發週期並降低技術風險。

採取切實可行的策略性舉措，包括技術模組化、供應鏈多元化和早期監管回應，以加速臨床開發並降低生產風險。

產業領導企業應採取多管齊下的策略，整合技術投資、供應鏈韌性和協作型商業模式，以維持其在加速減壓艙 (ADC) 領域的競爭力。首先，他們應投資於模組化製程平台和分析技術，以實現鍵合化學和有效載荷類型的快速切換。這種柔軟性將縮短技術轉移所需的時間，並有助於在各個臨床階段有效擴大生產規模。其次，他們應優先考慮關鍵原料和試劑的供應商多元化和區域冗餘，從而降低單一來源供應鏈帶來的關稅衝擊和中斷風險。

採用嚴謹的多方面調查方法，結合專家訪談、技術文獻綜述和情境分析，檢驗ADC製造的見解和實用建議。

本報告的調查方法結合了定性專家訪談、與關鍵相關人員的直接對話以及嚴謹的二手資料研究，以確保結論基於當前的實踐和技術現實。主要資料收集包括對參與抗體偶聯藥物（ADC）開發的生物製藥公司的生產科學家、品質和法規官員、採購負責人以及高階主管進行結構化訪談。透過這些對話，我們評估了產能限制、技術瓶頸以及合作夥伴選擇決策標準。

彙編了一系列關鍵發現，證明了為什麼綜合技術能力、供應鏈策略和監管遠見對於 ADC 專案的成功至關重要。

總之，隨著抗體藥物複合體（ADC）作為治療方法日益成熟，專業契約製造在提供安全、有效且商業性可行性的產品方面發揮著越來越重要的作用。產業趨勢表明，偶聯化學、連接子設計和有效載荷處理方面的技術進步將持續推動對能夠提供檢驗、可擴展製程和穩定監管結果的合作夥伴的需求。同時，不斷變化的貿易政策和區域性因素要求將供應鏈策略納入開發計劃，使其成為整體開發流程不可或缺的一部分，而不是事後才考慮的因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗體藥物複合體（ADC）契約製造市場：依服務類型分類

  • 分析
  • 零件製造
    • 抗體產生
    • 連接基團合成
    • 藥物分子合成
  • 結合/純化
  • 填充和精加工
  • 製程開發
    • 整合過程開發
    • 配方開發
  • 監管和CMC支持
  • 供應鏈物流

第9章：按連接子類型分類的抗體藥物複合體(ADC)契約製造市場

  • 可切割
    • 二硫鍵體系
    • 酵素敏感性
    • pH響應性
  • 非切割型

第10章：以有效載荷類型分類的抗體藥物複合體(ADC)契約製造市場

  • DNA損傷劑
    • 卡利切黴素
    • PBD二聚體
  • 微管抑制劑
    • 奧瑞他汀
      • 單甲基澳瑞他汀E
      • 單甲基澳瑞他汀F
    • 肌苷類化合物
      • M-丹參（DM1）
      • 愛 Tansine (DM4)
  • 拓樸異構酶抑制劑
    • 喜樹鹼
    • 多柔比星

第11章：抗體藥物複合體（ADC）的契約製造市場（依研發階段分類）

  • 臨床
    • 第一階段
    • 第二階段
    • 第三階段
    • 臨床前
  • 商業的

第12章：以劑型分類的抗體藥物複合體（ADC）契約製造市場

  • 墨水匣
  • 液體管瓶
  • 冷凍乾燥管瓶
  • 預填充式注射器

第13章：抗體藥物複合體（ADC）的契約製造市場：按應用領域分類

  • 非腫瘤區域
    • 自體免疫疾病
    • 感染疾病
    • 發炎性疾病
  • 腫瘤學
    • 乳癌
    • 血癌
    • 肺癌
    • 卵巢癌

第14章：抗體藥物複合體（ADC）的契約製造市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：抗體藥物複合體（ADC）契約製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：抗體藥物複合體（ADC）的契約製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國抗體藥物複合體（ADC）契約製造市場

第18章：中國抗體藥物複合體（ADC）契約製造市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Abzena Ltd.
  • AGC Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Limited
  • AstraZeneca PLC
  • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
  • Axplora Group GmbH
  • BSP Pharmaceuticals SpA
  • CARBOGEN AMCIS AG by Dishman Carbogen Amcis Ltd.
  • Catalent, Inc.
  • Cerbios-Pharma SA
  • Creative Biolabs Inc.
  • EirGenix, Inc.
  • Fujifilm Holdings Corporation
  • Goodwin Biotechnology, Inc.
  • Hangzhou DAC Biotech Co., Ltd.
  • Jubilant Pharmova Limited Company
  • Lonza Group Ltd.
  • Lotte Biologics Co., Ltd.
  • Merck KGaA
  • MicroBiopharm Japan Co., Ltd.
  • NJ Bio, Inc.
  • Pfizer Inc.
  • Piramal Pharma Limited
  • Recipharm AB
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • Sterling Pharma Solutions Limited
  • Syngene International Limited
  • WuXi Biologics Inc.
Product Code: MRR-B16853777700

The Antibody Drug Conjugates Contract Manufacturing Market was valued at USD 10.65 billion in 2025 and is projected to grow to USD 11.79 billion in 2026, with a CAGR of 10.98%, reaching USD 22.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.65 billion
Estimated Year [2026] USD 11.79 billion
Forecast Year [2032] USD 22.10 billion
CAGR (%) 10.98%

An authoritative framing of how specialized contract manufacturing transforms antibody drug conjugate development pathways and mitigates technical and operational risks

The antibody drug conjugates ecosystem is at a pivotal inflection, where advances in conjugation chemistry, payload diversity, and precision delivery converge with heightened demand for specialized contract manufacturing capabilities. This executive summary introduces the strategic importance of contract manufacturing in enabling developers to translate ADC concepts into clinical and commercial reality. It frames the discussion around capability gaps, technical complexity, and the operational milestones that separate successful scale-ups from stalled programs.

Over recent years, sponsors have increasingly outsourced complex ADC workstreams to specialized contract manufacturers to access deep technical expertise and mitigate capital intensity. Consequently, contract manufacturers now play a central role in bridging laboratory innovation and regulated manufacturing, managing activities that span antibody production, payload manufacture, linker synthesis, and the critical bioconjugation steps that define product quality. As such, understanding the end-to-end manufacturing landscape and modular service options is essential for portfolio planning and risk management.

This introduction also establishes the analytical lens used in the subsequent sections: an emphasis on technology readiness, regulatory alignment, supply chain resilience, and strategic partnerships. With that framing in place, the rest of this executive summary progresses from transformative industry shifts through regulatory and trade headwinds, segmentation dynamics, regional considerations, competitive behaviors, and concrete recommendations for leaders seeking to strengthen their ADC supply chains and accelerate clinical advancement.

How advances in conjugation chemistry, modular service models, and integrated quality systems are reshaping partner selection and manufacturing strategies for ADC developers

The ADC landscape is undergoing transformative shifts driven by scientific advances, evolving service delivery models, and a rebalancing of risk between sponsors and manufacturers. At the scientific level, innovations in linker chemistry, site-specific conjugation, and novel payload classes are expanding the therapeutic applications of ADCs while simultaneously raising the bar for manufacturing precision. These technical developments have, in turn, catalyzed demand for contract manufacturers that can demonstrate validated processes for consistent drug-to-antibody ratios, low aggregation, and robust impurity control.

Concurrently, service delivery models have matured beyond traditional full-service arrangements toward hybrid approaches that enable sponsors to select modular capabilities. End-to-end manufacturing remains attractive for programs that require a single point of accountability and integrated process control, whereas standalone and modular services are growing in appeal for sponsors seeking targeted expertise in antibody production, bioconjugation, cytotoxic payload manufacturing, fill-finish, or linker synthesis. This shift permits sponsors to optimize capital allocation and retain strategic control over specific elements of the value chain while outsourcing high-risk, specialized tasks.

Another major shift is the emergence of vertically integrated ecosystems where manufacturing partners pair deep technical competence with regulatory and quality systems experience. As a result, contract manufacturers who can provide seamless technology transfer, scalable process platforms, and a demonstrated track record in complex aseptic operations are commanding greater strategic relationships with sponsors. Finally, supply chain resilience and redundancy have risen to prominence, influencing site selection, inventory strategies, and contingency planning as sponsors seek to safeguard clinical timelines against raw material shortages and logistics disruptions.

Assessing how tariff dynamics and trade policy developments in 2025 are reshaping sourcing, facility siting, and risk mitigation strategies across ADC manufacturing value chains

Tariff policy developments in the United States during 2025 have introduced a new layer of complexity for ADC contract manufacturing strategies, influencing sourcing, cost structures, and strategic supply chain decisions. Increased tariffs on specific chemical intermediates, synthetic reagents, and certain imported biologics-related consumables have pressured manufacturers to reassess supplier relationships and consider nearshoring or dual-sourcing arrangements. In this context, tariffs operate as a strategic stress test that highlights dependencies within the upstream supply base, prompting firms to prioritize suppliers with compliant trade practices and secure logistics pathways.

As organizations respond, many are shifting procurement strategies to emphasize supplier diversification, longer-term contractual commitments, and qualified alternate sources. These approaches seek to reduce vulnerability to tariff fluctuations while preserving access to high-quality raw materials and specialized reagents. At the same time, tariff-driven cost pressures are incentivizing contract manufacturers to pursue process intensification, yield improvements, and raw-material substitution where feasible, thereby partially offsetting increased input costs through technical efficiency gains. This technical response can also reduce waste and improve overall process sustainability.

In parallel, tariff considerations are influencing geopolitical decisions about facility siting and investment. Sponsors and manufacturers are increasingly weighing the trade-offs between the operational advantages of specific manufacturing hubs and the financial implications of cross-border trade costs. Consequently, some organizations are accelerating initiatives to localize critical manufacturing steps or to partner with regional providers that can deliver capacity without incurring elevated import duties. The cumulative effect is greater emphasis on supply chain transparency, traceability, and contractual protections that account for tariff risk, as well as heightened collaboration between commercial, procurement, and technical teams to align sourcing strategy with program timelines.

How clinical stage, service architecture, payload and linker chemistry, and therapeutic application segmentation drive distinct manufacturing, quality, and strategic requirements

A granular understanding of segmentation is essential to align manufacturing capabilities with program objectives and regulatory expectations. Based on type, the market differentiates programs by clinical and commercial status, with the clinical segment further delineated into Phase I, Phase II, Phase III, and preclinical activities. Each phase imposes distinct technical and regulatory requirements, ranging from flexible small-batch production for early safety studies to controlled, validated processes for later-stage pivotal trials. Recognizing these distinctions enables manufacturers to tailor capacity and quality systems to sponsor needs while optimizing time-to-clinic.

Service offerings form another axis of segmentation that influences partner selection. The market includes end-to-end manufacturing models that provide a single accountable party for the full ADC lifecycle, as well as standalone or modular services that permit sponsors to combine specialist providers for antibody production, bioconjugation, cytotoxic payload manufacturing, fill-finish, and linker synthesis. This modularity supports strategic hybrids where sponsors retain control of certain elements while outsourcing high-complexity steps, thereby balancing risk, cost, and intellectual property considerations.

Payload type segmentation separates cytotoxic and non-cytotoxic payloads, a distinction that drives differences in containment, handling, and analytical testing requirements. Similarly, linker type segmentation divides processes into cleavable and non-cleavable strategies, with cleavable linkers further categorized into disulfide-based, enzyme-sensitive, and pH-sensitive chemistries; each class introduces unique stability and release profiles that must be tightly controlled during manufacture and storage. Finally, application-based segmentation splits ADC programs into oncology and non-oncology uses. Non-oncology applications include autoimmune diseases, infectious diseases, and inflammatory disorders, while oncology programs predominantly target disease areas such as breast cancer, hematologic cancers, lung cancer, and ovarian cancer. Taken together, these segmentation axes inform capacity planning, facility design, analytical development, and quality assurance strategies for contract manufacturers and sponsors alike.

Regional differences in capability, regulatory frameworks, and supply chain complexity that influence site selection, tech transfer, and contingency planning for ADC programs

Regional dynamics shape capability availability, regulatory interactions, and logistical complexity across global ADC manufacturing networks. In the Americas, centers of excellence combine advanced biologics manufacturing know-how with established regulatory frameworks that facilitate clinical and commercial transitions, while also presenting opportunities for localized sourcing and rapid market access. In contrast, Europe, Middle East & Africa feature diverse regulatory pathways and strong expertise in specialized chemistries and small-batch GMP operations, but sponsors must navigate heterogeneous national regulations and supply chain fragmentation when coordinating cross-border production.

Meanwhile, the Asia-Pacific region has become a critical node for capacity expansion, offering cost-competitive manufacturing, growing technical talent pools, and rapidly improving regulatory infrastructure. However, firms operating across these regions must manage complex logistics, customs regimes, and quality harmonization to ensure consistent product attributes and uninterrupted clinical supply. Thus, effective regional strategies blend local operational strengths with global quality systems and robust tech transfer processes.

Across all regions, proximity to skilled labor, availability of specialized raw materials, and the maturity of regional supply ecosystems influence partner selection and investment decisions. Sponsors and manufacturers that proactively align regional capabilities with program timelines and regulatory milestones reduce friction during scale-up and increase the probability of successful, timely study execution.

Why technical depth, validated quality systems, and proven regulatory performance are becoming the decisive differentiators among ADC contract manufacturing providers

Competitive dynamics among manufacturing organizations are shifting from pure capacity provision to value-driven differentiation rooted in technical competence, regulatory agility, and integrated service portfolios. Leading contract manufacturers are investing in specialized facilities for high-containment payload handling, establishing validated bioconjugation platforms, and expanding analytical capabilities to support advanced characterization of ADC critical quality attributes. These investments enable partners to move beyond transactional relationships toward strategic alliances that shorten development timelines and reduce technical risk.

In addition to capital projects, companies are differentiating through demonstrable expertise in technology transfer, regulatory support, and process development services that address the most failure-prone segments of ADC production. Strategic collaboration with academic groups and chemistry innovators is also enabling nimble adoption of emerging linker and conjugation technologies. At the same time, some organizations are selectively expanding geographic footprints to offer regional redundancy and to meet sponsor preferences for local manufacturing. These moves provide commercial flexibility and improve supply continuity for global programs.

Finally, the competitive landscape is marked by an emphasis on transparent quality systems, third-party certifications, and validated supply chains. Firms that can demonstrate consistent regulatory inspection performance, mature quality oversight, and proactive contamination control gain an advantage when sponsors evaluate manufacturing risk. As a result, companies that pair technical depth with reliable regulatory outcomes are positioned to capture long-term strategic contracts and collaborative product development relationships.

Practical and strategic actions including technology modularity, supply chain diversification, and early regulatory alignment to accelerate clinical progression and reduce manufacturing risk

Industry leaders should pursue a multi-pronged strategy that integrates technical investment, supply chain resilience, and collaborative commercial models to remain competitive in the ADC space. First, invest in modular process platforms and analytics that enable fast pivots between conjugation chemistries and payload classes; this flexibility reduces time lost to technology transfer and enables efficient scaling across clinical phases. Second, prioritize supplier diversification and regional redundancy for critical raw materials and reagents, thereby mitigating exposure to tariff shocks and single-source disruptions.

Next, strengthen regulatory engagement early in development by aligning manufacturing development plans with regulator expectations and by documenting control strategies for linker stability, payload impurities, and drug-to-antibody ratio consistency. In parallel, cultivate deeper technical partnerships with chemistry innovators and academic groups to stay at the leading edge of novel conjugation approaches while retaining options for selective in-licensing. Finally, develop business models that combine end-to-end offerings with modular services, allowing sponsors to customize engagements according to risk tolerance and IP strategy. Taken together, these actions will improve program robustness, accelerate timelines, and create more defensible, long-term partnerships between sponsors and manufacturing providers.

A rigorous, multi-source methodology combining expert interviews, technical literature review, and scenario analysis to validate insights and practical recommendations for ADC manufacturing

The research methodology underpinning this report blends qualitative expert interviews, primary stakeholder engagement, and rigorous secondary research to ensure conclusions are grounded in current practice and technical reality. Primary data collection included structured interviews with manufacturing scientists, quality and regulatory leads, procurement professionals, and biopharma executives involved in ADC development. These conversations informed assessments of capacity constraints, technical bottlenecks, and decision criteria used in partner selection.

Secondary research complemented interviews with a close review of scientific literature, regulatory guidance documents, and trade publications to validate technical claims around conjugation methodologies, impurity profiles, and analytical testing requirements. Where applicable, case studies and anonymized program examples were synthesized to illustrate successful technology transfers, mitigation of supply disruptions, and the practical application of risk-based quality approaches. Analytical rigor was maintained by cross-referencing insights from multiple independent sources and by subjecting hypotheses to validation through industry peer review.

Finally, the methodology incorporated a scenario-based approach to evaluate the impact of geopolitical and trade developments on supply chain decisions. This approach enabled the generation of actionable recommendations that are responsive to a range of operational conditions and aligned with sponsor priorities for speed, quality, and regulatory compliance.

Synthesis of key findings demonstrating why integrated technical capability, supply chain strategy, and regulatory foresight determine ADC program success

In conclusion, the maturation of antibody drug conjugates as a therapeutic modality has elevated the role of specialized contract manufacturing in delivering safe, effective, and commercially viable products. Industry trends indicate that technical sophistication in conjugation chemistry, linker design, and payload handling will continue to drive demand for partners who can demonstrate validated, scalable processes and consistent regulatory outcomes. Concurrently, trade policy shifts and regional considerations mean that supply chain strategy must be integral to development planning rather than an afterthought.

Sponsors and manufacturers that align investments in modular process platforms, analytics, and regional capacity with robust quality systems and proactive regulatory engagement will be best positioned to accelerate clinical milestones and to manage risk across the ADC lifecycle. Ultimately, the convergence of scientific progress and strategic manufacturing partnerships will determine which programs reach patients most efficiently and sustainably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibody Drug Conjugates Contract Manufacturing Market, by Service Type

  • 8.1. Analytical
  • 8.2. Component Manufacturing
    • 8.2.1. Antibody Production
    • 8.2.2. Linker Synthesis
    • 8.2.3. Payload Synthesis
  • 8.3. Conjugation & Purification
  • 8.4. Fill-Finish
  • 8.5. Process Development
    • 8.5.1. Conjugation Process Development
    • 8.5.2. Formulation Development
  • 8.6. Regulatory & CMC Support
  • 8.7. Supply Chain & Logistics

9. Antibody Drug Conjugates Contract Manufacturing Market, by Linker Type

  • 9.1. Cleavable
    • 9.1.1. Disulfide-based
    • 9.1.2. Enzyme-sensitive
    • 9.1.3. pH-sensitive
  • 9.2. Non-Cleavable

10. Antibody Drug Conjugates Contract Manufacturing Market, by Payload Type

  • 10.1. DNA-Damaging Agents
    • 10.1.1. Calicheamicin
    • 10.1.2. PBD Dimers
  • 10.2. Microtubule Inhibitors
    • 10.2.1. Auristatins
      • 10.2.1.1. Monomethyl auristatin E
      • 10.2.1.2. Monomethyl auristatin F
    • 10.2.2. Maytansinoids
      • 10.2.2.1. Emtansine (DM1)
      • 10.2.2.2. Ravtansine (DM4)
  • 10.3. Topoisomerase Inhibitors
    • 10.3.1. Camptothecins
    • 10.3.2. Doxorubicins

11. Antibody Drug Conjugates Contract Manufacturing Market, by Development Stage

  • 11.1. Clinical
    • 11.1.1. Phase I
    • 11.1.2. Phase II
    • 11.1.3. Phase III
    • 11.1.4. Preclinical
  • 11.2. Commercial

12. Antibody Drug Conjugates Contract Manufacturing Market, by Dosage Form

  • 12.1. Cartridge
  • 12.2. Liquid Vial
  • 12.3. Lyophilized Vial
  • 12.4. Prefilled Syringe

13. Antibody Drug Conjugates Contract Manufacturing Market, by Application

  • 13.1. Non-Oncology
    • 13.1.1. Autoimmune Diseases
    • 13.1.2. Infectious Diseases
    • 13.1.3. Inflammatory Disorders
  • 13.2. Oncology
    • 13.2.1. Breast Cancer
    • 13.2.2. Hematologic Cancers
    • 13.2.3. Lung Cancer
    • 13.2.4. Ovarian Cancer

14. Antibody Drug Conjugates Contract Manufacturing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antibody Drug Conjugates Contract Manufacturing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antibody Drug Conjugates Contract Manufacturing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Antibody Drug Conjugates Contract Manufacturing Market

18. China Antibody Drug Conjugates Contract Manufacturing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Abzena Ltd.
  • 19.7. AGC Inc.
  • 19.8. Ajinomoto Bio-Pharma Services
  • 19.9. Almac Group Limited
  • 19.10. AstraZeneca PLC
  • 19.11. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
  • 19.12. Axplora Group GmbH
  • 19.13. BSP Pharmaceuticals S.p.A.
  • 19.14. CARBOGEN AMCIS AG by Dishman Carbogen Amcis Ltd.
  • 19.15. Catalent, Inc.
  • 19.16. Cerbios-Pharma SA
  • 19.17. Creative Biolabs Inc.
  • 19.18. EirGenix, Inc.
  • 19.19. Fujifilm Holdings Corporation
  • 19.20. Goodwin Biotechnology, Inc.
  • 19.21. Hangzhou DAC Biotech Co., Ltd.
  • 19.22. Jubilant Pharmova Limited Company
  • 19.23. Lonza Group Ltd.
  • 19.24. Lotte Biologics Co., Ltd.
  • 19.25. Merck KGaA
  • 19.26. MicroBiopharm Japan Co., Ltd.
  • 19.27. NJ Bio, Inc.
  • 19.28. Pfizer Inc.
  • 19.29. Piramal Pharma Limited
  • 19.30. Recipharm AB
  • 19.31. Regeneron Pharmaceuticals, Inc.
  • 19.32. Samsung Biologics Co., Ltd.
  • 19.33. Sartorius AG
  • 19.34. Sterling Pharma Solutions Limited
  • 19.35. Syngene International Limited
  • 19.36. WuXi Biologics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONJUGATION & PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONJUGATION & PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONJUGATION & PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY FILL-FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY FILL-FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY FILL-FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONJUGATION PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONJUGATION PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONJUGATION PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGULATORY & CMC SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGULATORY & CMC SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGULATORY & CMC SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DISULFIDE-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DISULFIDE-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DISULFIDE-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ENZYME-SENSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ENZYME-SENSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ENZYME-SENSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PH-SENSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PH-SENSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PH-SENSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-CLEAVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-CLEAVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-CLEAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CALICHEAMICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CALICHEAMICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CALICHEAMICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PBD DIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PBD DIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PBD DIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MONOMETHYL AURISTATIN E, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MONOMETHYL AURISTATIN E, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MONOMETHYL AURISTATIN E, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MONOMETHYL AURISTATIN F, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MONOMETHYL AURISTATIN F, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MONOMETHYL AURISTATIN F, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY EMTANSINE (DM1), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY EMTANSINE (DM1), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY EMTANSINE (DM1), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY RAVTANSINE (DM4), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY RAVTANSINE (DM4), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY RAVTANSINE (DM4), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CAMPTOTHECINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CAMPTOTHECINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CAMPTOTHECINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOXORUBICINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOXORUBICINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOXORUBICINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CARTRIDGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CARTRIDGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CARTRIDGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LYOPHILIZED VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LYOPHILIZED VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LYOPHILIZED VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY INFLAMMATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY INFLAMMATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGIC CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGIC CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGIC CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COMPONENT MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY DNA-DAMAGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MICROTUBULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY AURISTATINS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MAYTANSINOIDS, 2018-